These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1590 related items for PubMed ID: 31634647

  • 1. Haematological immune-related adverse events with immune checkpoint inhibitors, how to manage?
    Michot JM, Lazarovici J, Tieu A, Champiat S, Voisin AL, Ebbo M, Godeau B, Michel M, Ribrag V, Lambotte O.
    Eur J Cancer; 2019 Nov; 122():72-90. PubMed ID: 31634647
    [Abstract] [Full Text] [Related]

  • 2. Haematological immune-related adverse events induced by anti-PD-1 or anti-PD-L1 immunotherapy: a descriptive observational study.
    Delanoy N, Michot JM, Comont T, Kramkimel N, Lazarovici J, Dupont R, Champiat S, Chahine C, Robert C, Herbaux C, Besse B, Guillemin A, Mateus C, Pautier P, Saïag P, Madonna E, Maerevoet M, Bout JC, Leduc C, Biscay P, Quere G, Nardin C, Ebbo M, Albigès L, Marret G, Levrat V, Dujon C, Vargaftig J, Laghouati S, Croisille L, Voisin AL, Godeau B, Massard C, Ribrag V, Marabelle A, Michel M, Lambotte O.
    Lancet Haematol; 2019 Jan; 6(1):e48-e57. PubMed ID: 30528137
    [Abstract] [Full Text] [Related]

  • 3. New insight in endocrine-related adverse events associated to immune checkpoint blockade.
    Elia G, Ferrari SM, Galdiero MR, Ragusa F, Paparo SR, Ruffilli I, Varricchi G, Fallahi P, Antonelli A.
    Best Pract Res Clin Endocrinol Metab; 2020 Jan; 34(1):101370. PubMed ID: 31983543
    [Abstract] [Full Text] [Related]

  • 4. The determinants of very severe immune-related adverse events associated with immune checkpoint inhibitors: A prospective study of the French REISAMIC registry.
    Ruste V, Goldschmidt V, Laparra A, Messayke S, Danlos FX, Romano-Martin P, Champiat S, Voisin AL, Baldini C, Massard C, Laghouati S, Marabelle A, Lambotte O, Michot JM.
    Eur J Cancer; 2021 Nov; 158():217-224. PubMed ID: 34627664
    [Abstract] [Full Text] [Related]

  • 5. Prevalence of immune-related systemic adverse events in patients treated with anti-Programmed cell Death 1/anti-Programmed cell Death-Ligand 1 agents: A single-centre pharmacovigilance database analysis.
    Le Burel S, Champiat S, Mateus C, Marabelle A, Michot JM, Robert C, Belkhir R, Soria JC, Laghouati S, Voisin AL, Fain O, Mékinian A, Coutte L, Szwebel TA, Dunogeant L, Lioger B, Luxembourger C, Mariette X, Lambotte O.
    Eur J Cancer; 2017 Sep; 82():34-44. PubMed ID: 28646772
    [Abstract] [Full Text] [Related]

  • 6. Mechanisms of immune-related adverse events during the treatment of cancer with immune checkpoint inhibitors.
    Weinmann SC, Pisetsky DS.
    Rheumatology (Oxford); 2019 Dec 01; 58(Suppl 7):vii59-vii67. PubMed ID: 31816080
    [Abstract] [Full Text] [Related]

  • 7. [Toxicity of immune checkpoints inhibitors].
    Delaunay M, Caron P, Sibaud V, Godillot C, Collot S, Milia J, Prévot G, Mazières J.
    Rev Mal Respir; 2018 Dec 01; 35(10):1028-1038. PubMed ID: 30213624
    [Abstract] [Full Text] [Related]

  • 8. Management of Adverse Events Following Treatment With Anti-Programmed Death-1 Agents.
    Weber JS, Postow M, Lao CD, Schadendorf D.
    Oncologist; 2016 Oct 01; 21(10):1230-1240. PubMed ID: 27401894
    [Abstract] [Full Text] [Related]

  • 9. Dermatologic Reactions to Immune Checkpoint Inhibitors : Skin Toxicities and Immunotherapy.
    Sibaud V.
    Am J Clin Dermatol; 2018 Jun 01; 19(3):345-361. PubMed ID: 29256113
    [Abstract] [Full Text] [Related]

  • 10. Autoimmune complications of immunotherapy: pathophysiology and management.
    Chan KK, Bass AR.
    BMJ; 2020 Apr 06; 369():m736. PubMed ID: 32253223
    [Abstract] [Full Text] [Related]

  • 11. [Immunotherapy is cancer treatment with a novel side-effect profile].
    Kondrup M, Raunkilde L, Svane IM, Schmidt H, Bastholt L.
    Ugeskr Laeger; 2017 Oct 02; 179(40):. PubMed ID: 28992844
    [Abstract] [Full Text] [Related]

  • 12. Characterization of liver injury induced by cancer immunotherapy using immune checkpoint inhibitors.
    De Martin E, Michot JM, Papouin B, Champiat S, Mateus C, Lambotte O, Roche B, Antonini TM, Coilly A, Laghouati S, Robert C, Marabelle A, Guettier C, Samuel D.
    J Hepatol; 2018 Jun 02; 68(6):1181-1190. PubMed ID: 29427729
    [Abstract] [Full Text] [Related]

  • 13. Immunopathogenesis of Immune Checkpoint Inhibitor-Related Adverse Events: Roles of the Intestinal Microbiome and Th17 Cells.
    Anderson R, Theron AJ, Rapoport BL.
    Front Immunol; 2019 Jun 02; 10():2254. PubMed ID: 31616428
    [Abstract] [Full Text] [Related]

  • 14. Immune-related adverse events in various organs caused by immune checkpoint inhibitors.
    Okiyama N, Tanaka R.
    Allergol Int; 2022 Apr 02; 71(2):169-178. PubMed ID: 35101349
    [Abstract] [Full Text] [Related]

  • 15. Immune-related adverse events associated with programmed cell death protein-1 and programmed cell death ligand 1 inhibitors for non-small cell lung cancer: a PRISMA systematic review and meta-analysis.
    Sun X, Roudi R, Dai T, Chen S, Fan B, Li H, Zhou Y, Zhou M, Zhu B, Yin C, Li B, Li X.
    BMC Cancer; 2019 Jun 10; 19(1):558. PubMed ID: 31182061
    [Abstract] [Full Text] [Related]

  • 16. Time to dissect the autoimmune etiology of cancer antibody immunotherapy.
    Dougan M, Pietropaolo M.
    J Clin Invest; 2020 Jan 02; 130(1):51-61. PubMed ID: 31895048
    [Abstract] [Full Text] [Related]

  • 17. Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance.
    Martins F, Sofiya L, Sykiotis GP, Lamine F, Maillard M, Fraga M, Shabafrouz K, Ribi C, Cairoli A, Guex-Crosier Y, Kuntzer T, Michielin O, Peters S, Coukos G, Spertini F, Thompson JA, Obeid M.
    Nat Rev Clin Oncol; 2019 Sep 02; 16(9):563-580. PubMed ID: 31092901
    [Abstract] [Full Text] [Related]

  • 18. Toxicities with Immune Checkpoint Inhibitors: Emerging Priorities From Disproportionality Analysis of the FDA Adverse Event Reporting System.
    Raschi E, Mazzarella A, Antonazzo IC, Bendinelli N, Forcesi E, Tuccori M, Moretti U, Poluzzi E, De Ponti F.
    Target Oncol; 2019 Apr 02; 14(2):205-221. PubMed ID: 30927173
    [Abstract] [Full Text] [Related]

  • 19. Multinational Association of Supportive Care in Cancer (MASCC) 2020 clinical practice recommendations for the management of severe gastrointestinal and hepatic toxicities from checkpoint inhibitors.
    Dougan M, Blidner AG, Choi J, Cooksley T, Glezerman I, Ginex P, Girotra M, Gupta D, Johnson D, Shannon VR, Suarez-Almazor M, Anderson R, Rapoport BL.
    Support Care Cancer; 2020 Dec 02; 28(12):6129-6143. PubMed ID: 32856210
    [Abstract] [Full Text] [Related]

  • 20. Molecular Mechanisms of Cutaneous Immune-Related Adverse Events (irAEs) Induced by Immune Checkpoint Inhibitors.
    Teng YS, Yu S.
    Curr Oncol; 2023 Jul 18; 30(7):6805-6819. PubMed ID: 37504358
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 80.